At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Proton Pump Inhibitors (PPI) and Fat Absorption in Subjects With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)
In Brief
A Phase 2 clinical trial evaluating Omeprazole 20mg Capsule and Placebo oral capsule for Pancreatic Insufficiency and Cystic Fibrosis. Completed, enrolled 19 participants across 1 site.
Detailed Summary
This is a clinical trial with a cross over design investigating the effect of the proton pump inhibitor omeprazole on fat malabsorption in subjects with cystic fibrosis and pancreatic insufficiency. Participants will be randomized to receive either omeprazole or placebo for 28 days, then cross over and receive omeprazole or placebo for another 28 days. Markers of fat absorption will be measured after each treatment course.
Study Details
Timeline
Interventions
Omeprazole 20mg daily for 28 days
Identically-appearing capsule to omeprazole for 28 days